(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 March 2012 (08.03.2012)

PCT

(10) International Publication Number
WO 2012/030394 A1

(51) International Patent Classification:
C07K 16/22 (2006.01) *A61K 39/395* (2006.01)
C07K 16/28 (2006.01) *A61P 9/10* (2006.01)

(21) International Application Number:
PCT/US2011/001536

(22) International Filing Date:
1 September 2011 (01.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/379,315 1 September 2010 (01.09.2010) US

(71) Applicant *(for all designated States except US)*: **GENZYME CORPORATION** [US/US]; 500 Kendall Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AKITA, Geoffrey Y.** [US/US]; 209 West St., Northborough, Massachusetts 01532 (US). **LONNING, Scott** [US/US]; 337 Olivia Dr., Northbridge, Massachusetts 01534 (US). **GREGORY, Richard C., Jr.** [US/US]; 369 Old Connecticut Path, Framingham, Massachusetts 01701 (US). **KUDEJ, Amelia B.** [US/US]; 9 Charles St., Westborough, Massachusetts 01589 (US).

(74) Agent: **NORTH, Christopher L.**; BUCHANAN INGERSOLL & ROONEY PC, P. O. Box 1404, Alexandria, Virginia 22313-1404 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: TREATMENT OF MYOCARDIAL INFARCTION USING TGF - BETA ANTAGONISTS




FIG. 1

(57) Abstract: Disclosed herein is a method of treating a patient suffering a myocardial infarction, particularly an acute myocardial infarction, or of reducing an adverse consequence of a myocardial infarction in a patient comprising administering an antagonist of TGF-β to the patient during the acute stage of the myocardial infarction.

WO 2012/030394 A1